MARKET

PAVM

PAVM

PAVmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.930
+0.040
+2.12%
After Hours: 1.930 0 0.00% 16:18 10/27 EDT
OPEN
1.870
PREV CLOSE
1.890
HIGH
1.950
LOW
1.850
VOLUME
339.12K
TURNOVER
--
52 WEEK HIGH
3.450
52 WEEK LOW
0.8100
MARKET CAP
95.80M
P/E (TTM)
-2.5644
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating PAVmed Inc. for Potential Breach of Fiduciary Duty Claims
NEW YORK, NY / ACCESSWIRE / October 6, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of PAVmed Inc.
ACCESSWIRE · 10/06 11:30
PAVmed files for $75M mixed shelf
PAVmed (PAVM) has filed a preliminary prospectus for a $75M mixed shelf offering.Shares down 2% after hours.
Seekingalpha · 09/10 20:34
PAVmed to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will present at the
GlobeNewswire · 09/08 14:30
PAVmed to Present at The LD 500 Virtual Conference
NEW YORK, NY / ACCESSWIRE / August 27, 2020 / PAVmed Inc.
ACCESSWIRE · 08/27 14:30
More info on PAVmed Q2 earnings
PAVmed (PAVM) Q2 reports GAAP loss of $5.6M or EPS of $ loss of $0.13, misses estimates.Non-GAAP adjusted loss of $4.2M or adjusted EPS loss of $0.09.Cash and cash equivalents of $7.1M as
Seekingalpha · 08/19 17:03
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q2 2020 Earnings Conference Call August 18, 2020 4:30 P.M.
Seeking Alpha - Transcript · 08/19 01:52
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
Conference call to be held today at 4:30 p.m. Eastern timeNEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today reported financial results for the three and six
GlobeNewswire · 08/18 21:14
PAVmed EPS misses by $0.02
PAVmed (PAVM): Q2 GAAP EPS of -$0.13 misses by $0.02.Cash and cash equivalents of $7.1M as of June 30.Shares -1.45% AH.Press release
Seekingalpha · 08/18 20:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PAVM. Analyze the recent business situations of PAVmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PAVM stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 6.62M
% Owned: 13.35%
Shares Outstanding: 49.64M
TypeInstitutionsShares
Increased
13
2.58M
New
34
1.19M
Decreased
5
447.56K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.13%
Healthcare Equipment & Supplies
+0.16%
Key Executives
Chairman/Chief Executive Officer/Director
Lishan Aklog
President/Chief Financial Officer/Secretary
Dennis McGrath
Vice Chairman/Independent Director
Michael Glennon
Executive Vice President
Brian DeGuzman
Independent Director
David Battleman
Independent Director
James Cox
Independent Director
Ronald Sparks
Independent Director
David Weild
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PAVM
PAVmed Inc. is a medical device company organized to conceive, develop and commercialize a diversified pipeline of products. The Company's products include PortIO, Caldus, CarpX, NextCath, DisappEAR and NextFlo. PortIO is an implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The Company's DisappEAR is an Antibiotic-eluting Resorbable Ear Tubes. The Company is engaged in developing and commercializing antibiotic-eluting resorbable ear tubes based on an aqueous silk technology conceived and developed at these institutions. The Company is engaged in developing disposable infusion system with variable flow resistors. Caldus is a disposable tissue ablation device.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of PAVmed Inc stock information, including NASDAQ:PAVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PAVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PAVM stock methods without spending real money on the virtual paper trading platform.